Breast cancer Posts on Medivizor
Navigation Menu

Breast cancer Posts on Medivizor

Fulvesterant compared to aromatase inhibitors in HR+ advance breast cancer in post-menopausal women

Posted by on Jul 16, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to look at the safety and effectiveness of fulvesterant (Faslodex) compared to aromatase inhibitors in post-menopausal women with hormone receptor positive (HR+) breast cancer. The authors found that fulvestrant was a safe and effective treatment in these patients when compared to aromatase inhibitors. Some...

Read More

Effects of breast reconstruction compared to mastectomy only on survival and risk of recurrence of breast cancer

Posted by on Jul 16, 2018 in Breast cancer | 0 comments

Layman Title Effects of breast reconstruction compared to mastectomy only on survival and risk of recurrence of breast cancer In a nutshell This study aimed to find out if breast reconstruction using deep inferior epigastric perforator (DIEP) flap reconstruction resulted in higher levels of recurrence compared to mastectomy alone. The authors found that...

Read More

Everolimus and exemstane for treatment of HR+/HER2- advanced or metastatic breast cancer

Posted by on Jul 16, 2018 in Breast cancer | 0 comments

In a nutshell This study looked at the effectiveness and safety of a combination of two cancer drugs, everolimus (Afinitor) and exemestane (Aromasin), in women after menopause with advanced breast cancer. The authors found that these drugs were safe and effective in the treatment of these women. Some background Breast cancer is...

Read More

Lymph node surgery for early stage breast cancer

Posted by on Jul 3, 2018 in Breast cancer | 0 comments

In a nutshell This study looked at the impact of removing lymph nodes (immune glands) from the armpit (axillary nodes) in the treatment of patients with breast cancer. The study found that removing the axillary lymph nodes did not signifcantly improve survival in patients with early stage breast cancer. Some background Breast cancer has the...

Read More

How BRCA mutations influence prognosis and “pathologically complete responses” when chemotherapy is used

Posted by on Jul 3, 2018 in Breast cancer | 0 comments

In a nutshell The study looked at the effect of BRCA1/BRCA2 mutations (abnormal genes) on the outcomes of patients treated for breast cancer. The study concluded that the patients who had the BRCA1/2 mutations were more responsive to treatment. Some background BRCA1 and BRCA2 are genes that stop tumors from being produced in the body. In some...

Read More

Using palbociclib alone or with other therapies in advanced ER+ breast cancer

Posted by on Jul 3, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to find out if the breast cancer treatment palbociclib (Ibrance) works better alone, or in combination with other endocrine therapies (drugs which act on hormone receptors) used to treat estrogen receptor positive (ER+ – a hormone receptor found on the tumor) breast cancer. The authors found that treating women...

Read More

Alopecia after breast cancer treatment

Posted by on Jul 3, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to find out how common persistent hair loss (alopecia) is after breast cancer chemotherapy, and how to prevent it. The authors found that persistent alopecia was present in all forms of chemotherapy but was worse with docetaxel (Taxotere) and could be prevented by using a scalp cooling technique. Some background...

Read More

Comparison of lapatinib and trastuzumab in patients with HER-2 receptor positive breast cancer

Posted by on Jul 2, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to compare lapatinib (Tykerb) and trastuzumab (Herceptin) in patients with HER-2 receptor positive breast cancer. This study found that in patients with hormone receptor-positive tumors, use of lapatinib for 6 months, followed by trastuzumab for 12 months significantly improved survival...

Read More